🧠 Updated Guidelines for Treatment Initiation of Restless Legs Syndrome (2025)

Source: American Academy of Sleep Medicine (AASM) Clinical Practice Guideline
Journal: Journal of Clinical Sleep Medicine (JCSM), 2025 Jan;21(1):137-152
PMID: 39324694 | Free PMC: Yes
Grade: GRADE Methodology
Developed by: Nonrespiratory Sleep Section, CHEST Sleep Medicine Network

#RLS #SleepMedicine #Neurology #AASM2025 #GRADE #Gabapentinoids #IronManagement

📋 Background

In 2025, the American Academy of Sleep Medicine released updated recommendations for the treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD), using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) methodology — a more rigorous, evidence-based approach than the 2012 guidelines.

🔑 Key Change: Why the Shift?

⚠️ Risk of augmentation with long-term dopamine agonist use is the primary driver of the major paradigm shift in the 2025 guidelines. Long-term pramipexole and ropinirole use leads to worsening of RLS symptoms (augmentation), making them less suitable for initial treatment.

📊 2012 vs 2025 Recommendations Comparison

2012 Guidelines

Non-GRADE methodology

➜

2025 Guidelines

GRADE methodology

2012 Recommendations

Level	Agents
Strong For	Pramipexole, Ropinirole
Conditional For	Levodopa, Gabapentin enacarbil
Optional	Gabapentin, Pregabalin, Carbamazepine, Supplemental iron

2025 Recommendations

Level	Agents
Strong For	Gabapentin, Gabapentin enacarbil, Pregabalin, IV Ferric carboxymaltose
Conditional For	Peroneal nerve stimulation (NEW), Opioids, Oral iron, Other IV iron, Dipyridamole
Conditional Against	Levodopa, Pramipexole, Ropinirole, Transdermal rotigotine, Carbamazepine, Clonazepam

💊 First-Line Treatments (2025 — Strong Recommendation)

1. Gabapentin & Gabapentin Enacarbil

Alpha-2-delta ligand anticonvulsants. Gabapentin enacarbil is a prodrug of gabapentin with improved bioavailability. Both reduce neuronal hyperexcitability implicated in RLS pathophysiology.

Dose: Gabapentin 300–2400 mg/day (divided doses); Gabapentin enacarbil 600–1800 mg once daily
Key advantage: No augmentation risk (unlike dopamine agonists)
Side effects: Dizziness, somnolence, peripheral edema

2. Pregabalin

Another alpha-2-delta ligand with similar mechanism. More predictable pharmacokinetics than gabapentin.

Dose: 75–450 mg/day (divided or BID)
Key advantage: Titrates smoothly, fewer GI side effects than gabapentin
Side effects: Dizziness, weight gain, ataxia at high doses

3. IV Ferric Carboxymaltose (FCM)

Intravenous iron formulation. Iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Brain iron deficiency is strongly linked to RLS pathophysiology.

Dose: 1000 mg IV infusion (single or divided dose)
Key advantage: Rapid repletion, bypasses GI absorption issues
Side effects: Hypophosphatemia (monitor), injection site reactions, transient dark stools

🥇 Second-Line & Conditional Options

Peroneal Nerve Stimulation (NEW — Conditional For)

Emerging non-pharmacological option. Surface electrical stimulation of the peroneal nerve reduces sensory symptoms and PLMS. Novel addition to the 2025 guidelines based on accumulating evidence.

Opioids (Conditional For)

Reserved for severe, refractory cases. Low-dose opioids (e.g., tramadol, oxycodone) may be considered when other treatments fail. Risk of dependence limits use.

Oral Iron (Conditional For)

First-line when ferritin is low. Ferrous sulfate 325 mg 1–2x daily with vitamin C for absorption. Requires 2–3 months for effect. Take on empty stomach.

Other IV Iron Formulations (Conditional For)

Iron sucrose, ferumoxytol as alternatives to FCM when FCM is unavailable or contraindicated.

Dipyridamole (Conditional For)

Adenosine antagonist with potential efficacy in RLS. Emerging evidence but mechanism not fully understood.

🚫 Treatments Now Conditional Against (2025)

Levodopa, Pramipexole, Ropinirole, Transdermal rotigotine — all dopamine agonists/precursors are now conditionally against their use as initial treatment due to augmentation risk.

Carbamazepine, Clonazepam — also conditional against due to unfavorable risk-benefit profile.

What is Augmentation?

Augmentation is the worsening of RLS symptoms (earlier onset, increased severity, shorter latency) with chronic dopamine agonist use. It can be severe and difficult to manage. Risk increases with duration of treatment, leading to the deprioritization of these agents in the 2025 guidelines.

🧪 Iron Management Protocol

Lab Protocol — Before Iron Studies

Draw iron studies fasting
Avoid red meat and iron supplements for 24 hours before blood draw

Treatment Thresholds & Algorithm

Ferritin Level	Transferrin Saturation	Recommendation
< 75 mcg/L	< 20%	Strong Oral iron + Vitamin C
75–100 mcg/L (max 300)	< 45%	Strong IV iron (preferably Ferric carboxymaltose) Repeat iron panel at 8 and 16 weeks post-infusion

When to Consider IV Iron Over Oral

No response to oral iron after 8–12 weeks
Need for rapid response (severe symptoms)
Malabsorption (e.g., IBD, celiac, bariatric surgery)
Non-compliance with oral iron (GI intolerance)
Ferritin 75–100 with TSat < 45%

📚 Supporting Evidence

Primary Guideline

Winkelman JW, Berkowski JA, DelRosso LM, et al. Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2025 Jan 1;21(1):137-152. doi:10.5664/jcsm.11390

PMID: 39324694 | Free PMC article

Systematic Review & Meta-Analysis

Winkelman JW, Berkowski JA, DelRosso LM, et al. Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2025 Jan 1;21(1):153-199. doi:10.5664/jcsm.11392

PMID: 39324664 | Free PMC article

2026 CHEST Infographic

🧬 Pathophysiology Rationale

RLS pathophysiology involves:

Brain iron deficiency — CSF ferritin is consistently low in RLS patients; iron is critical for dopamine synthesis (tyrosine hydroxylase requires iron)
Dopaminergic dysfunction — the A11 hypothalamic region projects to the spinal cord; impaired dopaminergic signaling causes sensorimotor symptoms
Central sensitization — gabapentinoids modulate calcium channels (alpha-2-delta subunit), reducing neuronal hyperexcitability
Glutamate dysregulation — increased glutamatergic activity in the thalamus and cortex contributes to sensory symptoms

📌 Clinical Takeaways

Always check iron first — Ferritin + Transferrin saturation before starting any RLS treatment
Gabapentinoids are now first-line — Gabapentin, pregabalin, gabapentin enacarbil
Avoid dopamine agonists as initial therapy — save for refractory cases with full understanding of augmentation risk
IV iron (FCM) for iron-deficient patients — especially when oral iron fails or is not tolerated
Augmentation = red flag — if a patient on dopamine agonist worsens over time, consider augmentation and transition to gabapentinoid
GRADE methodology — 2025 guidelines are more rigorous; recommendations reflect actual evidence quality

🔄 Switching Strategy (Augmentation)

If a patient develops augmentation on dopamine agonist:

Taper off dopamine agonist slowly (abrupt cessation can worsen RLS)
Start gabapentin or pregabalin concurrently
Consider IV iron if ferritin is low
Allow 2–4 weeks overlap during transition